Literature DB >> 8910590

Expression of rat aspartyl-tRNA synthetase in Saccharomyces cerevisiae. Role of the NH2-terminal polypeptide extension on enzyme activity and stability.

F Agou1, J P Waller, M Mirande.   

Abstract

Cytoplasmic aspartyl-tRNA synthetase from mammals is one of the components of a multienzyme complex comprising nine synthetase activities. The presence of an amino-terminal extension composed of about 40 residues is a characteristic of the eukaryotic enzyme. We report here the expression in the yeast Saccharomyces cerevisiae of a native form of rat aspartyl-tRNA synthetase and of two truncated derivatives lacking 20 or 36 amino acid residues from their amino-terminal polypeptide extension. The three recombinant enzyme species were purified to homogeneity. They behave as alpha2 dimers and display catalytic parameters in the tRNA aminoacylation reaction identical to those determined for the native, complex-associated form of aspartyl-tRNA synthetase isolated from rat liver. Because the dimer dissociation constant of rat AspRS is much higher than that of its bacterial and yeast counterparts, we could establish a direct correlation between dissociation of the dimer and inactivation of the enzyme. Our results clearly show that the monomer is devoid of amino acid activation and tRNA aminoacylation activities, indicating that dimerization is essential to confer an active conformation on the catalytic site. The two NH2-terminal truncated derivatives were fully active, but proved to be more unstable than the recombinant native enzyme, suggesting that the polypeptide extension fulfills structural rather than catalytic requirements.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910590     DOI: 10.1074/jbc.271.46.29295

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The tRNA-binding moiety in GCN2 contains a dimerization domain that interacts with the kinase domain and is required for tRNA binding and kinase activation.

Authors:  H Qiu; J Dong; C Hu; C S Francklyn; A G Hinnebusch
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  A recurrent general RNA binding domain appended to plant methionyl-tRNA synthetase acts as a cis-acting cofactor for aminoacylation.

Authors:  M Kaminska; M Deniziak; P Kerjan; J Barciszewski; M Mirande
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

3.  Small-angle X-ray solution scattering study of the multi-aminoacyl-tRNA synthetase complex reveals an elongated and multi-armed particle.

Authors:  José Dias; Louis Renault; Javier Pérez; Marc Mirande
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

4.  A domain in the N-terminal extension of class IIb eukaryotic aminoacyl-tRNA synthetases is important for tRNA binding.

Authors:  M Frugier; L Moulinier; R Giegé
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

5.  Monoclonal antibodies against tyrosyl-tRNA synthetase and its isolated cytokine-like domain.

Authors:  Iuliia Kondratiuk; Antonina Khoruzenko; Olga Cherednyk; Valeriy Filonenko; Aleksander Kornelyuk
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-06

6.  Arc1p is required for cytoplasmic confinement of synthetases and tRNA.

Authors:  Marie-Pierre Golinelli-Cohen; Marc Mirande
Journal:  Mol Cell Biochem       Date:  2006-11-25       Impact factor: 3.842

7.  3-Dimensional architecture of the human multi-tRNA synthetase complex.

Authors:  Krishnendu Khan; Camelia Baleanu-Gogonea; Belinda Willard; Valentin Gogonea; Paul L Fox
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

8.  Crystal structure of tRNA m1G9 methyltransferase Trm10: insight into the catalytic mechanism and recognition of tRNA substrate.

Authors:  Zhenhua Shao; Wei Yan; Junhui Peng; Xiaobing Zuo; Yang Zou; Fudong Li; Deshun Gong; Rongsheng Ma; Jihui Wu; Yunyu Shi; Zhiyong Zhang; Maikun Teng; Xu Li; Qingguo Gong
Journal:  Nucleic Acids Res       Date:  2013-09-29       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.